tailieunhanh - báo cáo hóa học:" Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010 | Brinckmann et al. Journal of Translational Medicine 2011 9 40 http content 9 1 40 JOURNAL OF TRANSLATIONAL MEDICINE REVIEW Open Access Rational design of HIV vaccines and microbicides report of the EUROPRISE network annual conference 2010 1 2 3 4 2 5 Sarah Brinckmann Kelly da Costa Marit J van Gils David Hallengard Katja Klein Luisa Madeira I l i Ỉnotti6 7 DTir ilr D ỉlmTỉ8 D I IQ9 Pi2 i 4 Doinh rt 10 í Ì3r Dell iHdcfarv11 HirT tHc Di iff if i 4 Laia Mainetti Paolo Palma Katharina Raue David Reiniiait Maic Reudelsteiz Nicolas Ruffin Janna Seifried11 Katrein Schafer12 Enas Sheik-Khalil13 Annette Skold14 Hannes Uchtenhagen14 Nicolas Vabret15 Serena Ziglio16 Gabriella Scarlatti6 Robin Shattock2 Britta Wahren4 and Frances Gotch17 Abstract Novel exciting intervention strategies to prevent infection with HIV have been tested in the past year and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners GSK Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries Tanzania Mozambique South Africa Kenya Malawi Rwanda and is directly supporting clinical trials including MABGEL a gp140-hsp70 conjugate trial and HIVIS vaccine trials in Europe and Africa. Introduction It seems clear that the EUROPRISE-sponsored studies reported herein are evolving within a dynamic HIV prevention landscape. .